← Back to Search

HIV/HCV Testing for Substance Use Disorder

N/A

Recruiting

Led By Jemima Frimpong, PhD

Research Sponsored by Columbia University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up the period 7-12 months post site-randomization (t3).

Awards & highlights

No Placebo-Only Group

Summary

This trial will test two active interventions to improve HIV testing and linkage to care among patients in substance use disorder treatment.

Who is the study for?

This trial is for opioid treatment programs (OTPs) that see at least 150 patients a year and can collect data on HIV/HCV testing and care. OTPs must be willing to share patient demographics, test reimbursement details, and have staff agree to participate in surveys and coaching.

What is being tested?

The study tests two 'practice coaching' interventions aimed at improving HIV and HCV testing rates in OTPs. One focuses solely on HIV, while the other addresses both HIV/HCV. Their effectiveness will be compared with a control group receiving only information.

What are the potential side effects?

Since this trial involves practice interventions rather than medications, there are no direct side effects like those associated with drugs. However, changes in clinic practices could affect patient experience or workflow.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ the period 7-12 months post site-randomization (t3).

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~the period 7-12 months post site-randomization (t3).

This trial's timeline: 3 weeks for screening, Varies for treatment, and the period 7-12 months post site-randomization (t3). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Proportion of OTP patients HIV tested at 6 months post intervention or control, while controlling for HIV testing during the baseline period (T1)

Secondary study objectives

Proportion of OTP patients HIV tested at 12 months post intervention or control

Other study objectives

OTPs' incremental cost-effectiveness ratio (ICER)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Group I: Information Control GroupExperimental Treatment1 Intervention

The administrators of OTPs assigned to the control condition will receive a website link to and hard copy of the NIDA/SAMHSA Blending Initiative product for HIV rapid testing.

Group II: HIV and HCV Testing Practice Coaching Intervention GroupExperimental Treatment1 Intervention

The HIV and HCV Testing Practice Coaching (PC) Intervention will leverage the HIV PC intervention and follow the same interventional steps described above, and, in addition, provide information and training to support joint HIV/HCV testing and linkage to care among OTP patients.

Group III: HIV Testing Practice Coaching Intervention GroupExperimental Treatment1 Intervention

The HIV Testing Practice Coaching (PC) Intervention is designed to improve the provision and sustained implementation of on-site HIV testing and linkage to care among OTP patients.

Do I qualify?Apply below to find out